Baxter International Faces Class Action Over Undisclosed Device Defects, Investors May Claim Compensation
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 23 minutes ago0mins
- Lawsuit Notification: Rosen Law Firm reminds investors who purchased Baxter International (NYSE:BAX) common stock between February 23, 2022, and July 30, 2025, to apply as lead plaintiffs by December 15, 2025, to participate in the class action and potentially receive compensation.
- Compensation Mechanism: Investors can join the lawsuit through a contingency fee arrangement that requires no upfront payment, indicating that Rosen Law Firm will provide legal support to ensure their rights are protected.
- Disclosure of Device Defects: The lawsuit alleges that Baxter failed to disclose systemic defects in its Novum LVP devices, leading to serious patient risks, including underinfusion and overinfusion, which could result in death, thereby impacting the company's reputation and future sales.
- Market Reaction: As details of the lawsuit emerge, investors face losses, and the false statements regarding the safety and sales prospects of Baxter's products may lead to a loss of customer confidence, adversely affecting the company's future market performance.
BAX.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on BAX
Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is 23.67 USD with a low forecast of 19.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
2 Buy
7 Hold
1 Sell
Hold
Current: 18.260
Low
19.00
Averages
23.67
High
36.00
Current: 18.260
Low
19.00
Averages
23.67
High
36.00
Citi
Neutral
maintain
$21
2025-12-11
New
Reason
Citi
Price Target
$21
2025-12-11
New
maintain
Neutral
Reason
Citi opens an "upside 90-day catalyst watch" on Baxter while keeping a Neutral rating on the shares with a $21 price target. The firm sees the upcoming guidance from new management as a "clearing event."
Morgan Stanley
Patrick Wood
Underweight
downgrade
$19 -> $15
2025-12-02
Reason
Morgan Stanley
Patrick Wood
Price Target
$19 -> $15
2025-12-02
downgrade
Underweight
Reason
Morgan Stanley analyst Patrick Wood lowered the firm's price target on Baxter to $15 from $19 and keeps an Underweight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
Goldman Sachs
David Roman
Neutral
downgrade
$25 -> $22
2025-10-31
Reason
Goldman Sachs
David Roman
Price Target
$25 -> $22
2025-10-31
downgrade
Neutral
Reason
Goldman Sachs analyst David Roman lowered the firm's price target on Baxter to $22 from $25 and keeps a Neutral rating on the shares. Total sales of $2.84B came in slightly below guidance and consensus, with shortfalls across all segments, most notably in MPT and Pharma, the analyst tells investors in a research note. Gross margins declined sharply to 39.4%, pressured by manufacturing variances expected to persist into 4Q25 and early 2026, though lower R&D and SG&A spending partially offset the impact. Management reduced FY25 organic growth and EPS guidance to 1%-2% and $2.35-$2.40, respectively, implying near-term softness and limited visibility into 2026, where earnings headwinds are expected to outweigh tailwinds, the firm says.
Argus
Steve Silver
Buy
to
Hold
downgrade
2025-10-31
Reason
Argus
Steve Silver
Price Target
2025-10-31
downgrade
Buy
to
Hold
Reason
Argus analyst Steve Silver downgraded Baxter to Hold from Buy.
See All Ratings
About BAX
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the main allegations in the class action lawsuits against Baxter?
How did Baxter's alleged supply chain misrepresentation impact its stock prices?
How might the lawsuits affect Baxter's financial performance in the next fiscal year?
What could be the long-term impact of these lawsuits on Baxter's reputation?